Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether 100mg erlotinib had similar effect compared
with 150mg erlotinib in NSCLC patients with EGFR mutation in China.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University